Bone Therapeutics

Regenerative Medicine for Bone Diseases


Bone Therapeutics is a regenerative therapy company specializing in addressing unmet medical needs in the field of bone diseases and orthopaedics. The company is bringing a new and unique treatment paradigm in this field with novel differentiated bone-forming cells administered via a minimally invasive percutaneous approach, offering significant benefits over the current standard of care which involves heavy surgery and long recovery periods.

Today, Bone Therapeutics has 2 first-in-class products, addressing multiple indications, in clinical development:

  • PREOB®, an autologous osteoblastic cell product currently in phase III clinical trials for the treatment of osteonecrosis and non-union fractures, and in a phase I/IIa for severe osteoporosis.
  • ALLOB®, an allogeneic (“off-the-shelf”) osteoblastic cell product currently in a phase I/IIa for the treatment of delayed union.

With two pivotal “phase III” and two “phase II” trials ongoing, Bone Therapeutics can be considered as the most advanced regenerative company in its field. Moreover, ongoing pre-clinical programs, targeting other indications, and derived products should allow the company to further leverage its unique knowledge of the bone physiology and long-standing expertise in bone regeneration.

Bone Therapeutics’ regenerative products are manufactured to the highest GMP standards, comply with all regulations and are protected by a rich IP estate covering 11 patent families.

Founded in 2006, Bone Therapeutics is privately held and headquartered in Gosselies (south of Brussels), Belgium.


Please select an option from the menu below:

Latest news


Bone Therapeutics SA
8 Rue Adrienne Bolland
6041 Gosselies - Belgium [Europe]
Tel: +32 (0)2 529 59 90
Fax : +32(0)2 529 59 93